查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456965

全球输血诊断市场 - 2024 年至 2029 年预测

Global Blood Transfusion Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年输血诊断市场规模为42.3亿美元，预估在预测期间内复合年增长率为6.07%，至2029年市场总规模达63.89亿美元。

输血诊断是指在输血给病人之前对血液或血液成分进行的检查。为了避免副作用和感染疾病传播，必须对每个血液单位进行血型和疾病筛检。它是输血治疗的重要组成部分，因为它为医疗保健专业人员提供重要资讯并检验捐赠者和受血者血液样本的兼容性。红血球是最常输注的血液製品。分子血型诊断是输血诊断的一种。对于具有临床相关、稀有或弱抗原抗体的患者，分子血型可以实现更安全的血液储存和按需供应。

开发中国家缺乏足够的血库、输血所需的医疗设备以及适当的血液储存条件，限制了血液供应以满足高需求。医院缺乏进行卫生和安全输血的必要设备。因此，慢性病负担的增加和捐赠者筛检需求的增加正在推动市场的成长。此外，由于外伤、交通事故和外科手术导致的输血需求不断增加，也对市场产生了积极影响。

市场领先的先进分子平台的出现正在加速从手动测试和仪器向半自动化和全自动仪器的转变。这些自动化系统对于检测血液样本中的输血传染感染疾病(TTI) 至关重要，并且可以准确消除整个输血过程中的人为错误。

在预测期内，北美预计将成为输血诊断市场最大的区域市场。这一优势得益于输血程序接受度的提高、公众对捐血意识的提高以及医疗基础设施的发展。根据国家生物技术资讯中心公布的资料，美国每年输血量超过1,500万单位，全球整体估计有8,500万单位输血量。

市场驱动因素：

  • 对血液和血液成分的高需求预计将推动市场成长。

血友病、癌症、血小板减少性疾病和慢性肾臟病（CKD）等血液相关疾病的盛行率不断上升，增加了对输血的需求。根据世界肾臟日估计，2020年全球约有8.5亿人将患有肾臟疾病。慢性肾臟病(CKD) 影响十分之一的人，预计到 2040年终将成为第六大死因。此外，越来越多的贫血患者需要输红血球进行治疗，进一步推动了对输血诊断的需求。世界卫生组织 (WHO) 估计全球约有 16.2 亿人患有贫血症。再加上已开发国家和开发中国家透过各种措施提高了对感染疾病血液安全的认识，正在推动对血液筛检测试和其他诊断设备的需求。

市场限制因素：

  • 设备高成本、基础设施缺乏

儘管慢性血液疾病的盛行率不断上升，输血需求不断增加，但仍有几个问题阻碍了市场的成长。造成这种情况的原因之一是缺乏对卫生基础设施的投资和严格的政府政策，特别是与开发中国家。此外，测试、设备和试剂的高成本以及缺乏处理自动化诊断解决方案的合格专业人员也是限制输血诊断市场在预测期内成长的因素。

竞争考察：

州输血委员会 (SBTC)相关人员于 2021 年 9 月报告称，马哈拉斯特拉邦的血库仅够一周的供应。这一下降是由于捐血减少、大流行导致的捐血者减少以及全州办公室和设施的关闭。

2021 年 9 月，美国红十字会发起了一项新的全国倡议，旨在接触更多黑人捐血，帮助镰状疾病患者并改善他们的健康状况。不仅血型相同，而且种族和民族相同的人的捐血是治疗镰状细胞患者的最可靠的选择。

主要进展

  • 2023 年 3 月 - MedGenome Labs 推出 FSHD1 基因筛检测试，即光学基因组图谱测试 (OGM)，以评估 1 型面肩肱型肌肉肌肉萎缩症(FSHD1) 患者的早期基因变化。这种先进的诊断工具采用先进的技术来全面、准确地评估遗传变化，检测大规模插入和重复以及细微的 DNA 变化。
  • 2021 年 5 月 - F. Hoffmann-La Roche Ltd 和 Bio-Rad Laboratories, Inc. 合作，为客户提供 Bio-Rad 的 InteliQ 产品和 Unity QC资料管理解决方案。此合作伙伴关係旨在提高工作流程效率并提高实验室的分析效能。 Bio-Rad 的 InteliQ 产品（包括带条码的品管管）是此合作伙伴关係的一部分。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球输血诊断市场：依类型

  • 介绍
  • 装置
  • 套件和试剂

第六章全球输血诊断市场：依技术分类

  • 介绍
  • ELISA
  • 西方印渍术
  • 核酸扩增
  • 其他的

第七章全球输血诊断市场：依最终使用者分类

  • 介绍
  • 医院/诊所
  • 诊断实验室
  • 血库

第八章全球输血诊断市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Quotient Ltd.
  • BAG Healthcare
  • Abbott
  • Immucor
  • Diasorin SPA
  • Bio-Rad Laboratories Inc.
  • Grifols SA
  • F. Hoffmann La Roche Ltd.
  • Beckman Coulter Inc.
  • DIAGAST
简介目录
Product Code: KSI061611612

The global blood transfusion diagnostics market was valued at US$4.230 billion in 2022 and is expected to grow at a CAGR of 6.07% over the forecast period to reach a total market size of US$6.389 billion by 2029.

Blood transfusion diagnostics refers to testing conducted on blood and blood components before transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients with antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.

Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market's growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favorably influencing the market.

The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.

During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.

MARKET DRIVER:

  • Blood and blood components are in high demand is anticipate in the market growth

The rising prevalence of blood-related conditions such as hemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.

MARKET RESTRAINTS:

  • The high cost of instruments and a lack of infrastructure

Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market's growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.

Competitive insight:

Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.

The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.

Key Developments:

  • March 2023- MedGenome Labs has introduced the FSHD1 genetic screening test, the Optical Genome Mapping Test (OGM), to assess early-stage genetic changes in patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). This advanced diagnostic tool uses advanced technology to provide a comprehensive and accurate assessment of genetic changes, detecting both large-scale insertions and duplications, as well as subtle DNA changes.
  • May 2021- F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories, Inc. have partnered to offer customers access to Bio-Rad's InteliQ products and Unity QC data management solutions. The partnership aims to enhance workflow efficiency and improve analytical performance in laboratories. Bio-Rad's InteliQ products, including barcoded quality control tubes, are part of the alliance.

Segmentation:

By Type

  • Instruments
  • Kits & Reagents

By Technology

  • ELISA
  • Western Blotting
  • Nucleic Acid Amplification
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostic Labs
  • Blood Banks

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Instruments
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Kits & Reagents
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. ELISA
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Western Blotting
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Nucleic Acid Amplification
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Labs
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Blood Banks
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Technology
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Technology
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Technology
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Technology
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Quotient Ltd.
  • 10.2. BAG Healthcare
  • 10.3. Abbott
  • 10.4. Immucor
  • 10.5. Diasorin SPA
  • 10.6. Bio-Rad Laboratories Inc.
  • 10.7. Grifols S.A.
  • 10.8. F. Hoffmann La Roche Ltd.
  • 10.9. Beckman Coulter Inc.
  • 10.10. DIAGAST